Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

Macular Edema Market Global Pipeline Review Research for H2 2016
  • USA - English


News provided by

ReportsnReports

01 Feb, 2017, 22:30 IST

Share this article

Share toX

Share this article

Share toX

PUNE, India, February 1, 2017 /PRNewswire/ --

ReportsnReports.com adds "Macular Edema - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Macular Edema (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Browse 26 market data tables and 12 figures, spread across 63 pages is available at http://www.reportsnreports.com/reports/755870-macular-edema-pipeline-review-h2-2016.html .

Companies discussed in this Macular Edema Pipeline Review, H2 2016 report include ActiveSite Pharmaceuticals, Inc., Ampio Pharmaceuticals, Inc., Chong Kun Dang Pharmaceutical Corp., Clearside BioMedical, Inc., Coherus BioSciences, Inc., Mabion SA, Pfizer Inc., Precision Ocular Ltd, Promedior, Inc., Taiwan Liposome Company, Ltd., Valeant Pharmaceuticals International, Inc. and Xbrane Biopharma AB. Drug Profiles mentioned in this research report are (aflibercept + triamcinolone acetonide), ACX-107, ASPPDC-020, BLO-021, celecoxib, danazol, dexamethasone sodium phosphate SR, HO-10, PRM-167 and ranibizumab biosimilar.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 2, 9, 1 and 1 respectively. Macular Edema.

Order a Purchase Copy of this Report @ http://www.reportsnreports.com/purchase.aspx?name=755870.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Macular Edema and reviews pipeline therapeutics for Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Macular Edema therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Macular Edema.

Another newly published market research report titled on Diabetic Retinopathy - Pipeline Review, H2 2016 (http://www.reportsnreports.com/reports/755878-diabetic-retinopathy-pipeline-review-h2-2016.html) provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development are Acucela Inc., Aerie Pharmaceuticals, Inc., Aerpio Therapeutics, Inc., Amakem NV, Antisense Therapeutics Limited, Araim Pharmaceuticals, Inc., BCN Peptides, S.A., Biomar Microbial Technologies, Charlesson LLC., Coherus BioSciences and more.

Explore more reports on Pharmaceuticals Market http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:   

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.